Carl Dambkowski - 03 Jun 2026 Form 4 Insider Report for Apogee Therapeutics, Inc. (APGE)

Reporting relationship: Chief Medical Officer
Issuer ticker: APGE
Reported as of: 03 Jun 2026
Net transaction value: -$432,905
SEC form: 4
Accepted by SEC: 05 Jun 2026, 20:00:14 UTC
Prior SEC filing: 03 Jun 2026
Next SEC filing: 12 Jun 2026
Source filing: View source filing
Reporting owner signature: /s/ Matthew Batters, as attorney-in-fact for Carl Dambkowski

Key filing fact

Carl Dambkowski filed Form 4 for Apogee Therapeutics, Inc. (APGE) on 05 Jun 2026.

Key facts

This page summarizes Carl Dambkowski's Form 4 filing for Apogee Therapeutics, Inc. (APGE).
3 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 05 Jun 2026, 20:00.

Change

Previous filing in this sequence was filed on 03 Jun 2026.
Current net transaction value: -$432,905.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001983476 Primary reporting owner

Dambkowski Carl

Relationship: Chief Medical Officer
Address: C/O APOGEE THERAPEUTICS, INC., 221 CRESCENT ST., BLDG. 17, STE. 102B, WALTHAM
Signature: /s/ Matthew Batters, as attorney-in-fact for Carl Dambkowski
Signature date: 05 Jun 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

APGE transaction

Common Stock

Options Exercise

Transaction value
Shares: +4,125
Change %: +2%
Price: $22.86^*
Shares after: 211,148
Date: 03 Jun 2026
Ownership: Direct

APGE transaction

Common Stock

Sale

Transaction value: $432,905
Shares: -5,500
Change %: -2.6%
Price: $78.71
Shares after: 205,648
Date: 03 Jun 2026
Ownership: Direct
Footnotes: F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

APGE transaction Derivative

Stock Option (Right to Buy)

Options Exercise

Transaction value
Shares: -4,125
Change %: -3.4%
Price: $0.000000^*
Shares after: 118,915
Date: 03 Jun 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 4,125
Exercise price: $22.86
Footnotes: F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Rule 10b5-1 trading plan

These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.

Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).

Explanation of responses 2 footnotes

Footnote F1

This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 22, 2025.

Footnote F2

This option represents the right to purchase 175,345 shares of the Issuer's common stock, which will vest in forty-eight equal monthly installments through December 18, 2027, subject to the Reporting Person's continued service to the Issuer.